



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy

Cryoablation of Tumors (Excluding Liver or Prostate Tumors)

Policy #: 429

Latest Review Date: July 2023

Category: Surgery

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Blue Advantage will treat **cryosurgical ablation of localized renal cell carcinoma that is no more than 4 cm in size** as a **covered benefit** when performed as open, laparoscopically, or percutaneously when **either** of the following criteria is met:

- Preservation of kidney function is necessary (i.e., the individual has 1 kidney or renal insufficiency defined by a glomerular filtration rate [GFR] of less than 60 mL/min/m²) and standard surgical approach (i.e., resection of renal tissue) is likely to substantially worsen kidney function; **OR**
- The individual is not considered a surgical candidate.

Blue Advantage will treat **cryosurgical ablation** as a **covered benefit** for the treatment of individuals with **osteolytic bone metastases that have failed or are poor candidates for standard treatments such as radiation and opioids**.

Blue Advantage will treat **cryosurgical ablation** to treat **lung cancer** as a **covered benefit** when **either** of the following criteria is met:

- The individual has early-stage non-small cell lung cancer and is a poor surgical candidate; **OR**
- The individual requires palliation for a central airway obstructing lesion.

Blue Advantage will treat **cryosurgical ablation** as a **non-covered benefit** when used to treat any of the following (including but not limited to):

- Benign or malignant tumors of the breast, lung (other than defined above), pancreas, or bone (other than defined above)
- Other solid tumors or metastases outside the liver and prostate, including desmoid tumors
- Renal cell carcinomas in individuals who are surgical candidates

-
- Please refer to Policy #178 ‘MRI-Guided Focused Ultrasound (MRgFUS)’ for coverage information on ultrasound ablation of the bone.
 - Please refer to Policy #119 ‘Radiofrequency Ablation of Solid Tumors Excluding Liver Tumors’ for radiofrequency ablation of renal, bone, and lung tumors.
 - Please refer to NCD for Cryosurgery of Prostate (230.9)
 - Please refer to Policy #070 ‘Locoregional Therapies for Hepatocellular Carcinoma and Metastatic Liver Carcinoma and Metastatic Carcinoid Tumors of the Liver’ for locoregional therapies for liver tumors.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most

appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Cryosurgical ablation (hereafter referred to as cryosurgery or cryoablation) involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Breast Tumors

Early-stage primary breast cancers are treated surgically. The selection of lumpectomy, modified radical mastectomy, or another approach is balanced against the patient's desire for breast conservation, the need for tumor-free margins in resected tissue, and the patient's age, hormone receptor status, and other factors. Adjuvant radiotherapy decreases local recurrences, particularly for those who select lumpectomy. Adjuvant hormonal therapy and/or chemotherapy are added, depending on presence and number of involved nodes, hormone receptor status, and other factors. Treatment of metastatic disease includes surgery to remove the lesion and combination chemotherapy.

Fibroadenomas are common benign tumors of the breast that can present as a palpable mass or a mammographic abnormality. These benign tumors are frequently surgically excised to rule out a malignancy.

Lung Tumors and Lung Metastases

Early-stage lung tumors are typically treated surgically. Patients with early-stage lung cancer who are not surgical candidates may be candidates for radiotherapy with curative intent. Cryoablation is being investigated in patients who are medically inoperable, with small primary lung cancers or lung metastases from extrapulmonary primaries. Patients with a more advanced local disease or metastatic disease may undergo chemotherapy with radiation following resection. Treatment is rarely curative; rather, it seeks to retard tumor growth or palliate symptoms.

Pancreatic Cancer

Pancreatic cancer is a relatively rare solid tumor that occurs almost exclusively in adults, and it is largely considered incurable. Surgical resection of tumors contained entirely within the pancreas is currently the only potentially curative treatment. However, the nature of the cancer is such that few tumors are found at such an early and potentially curable stage. Patients with more advanced local disease or metastatic disease may undergo chemotherapy with radiation following resection. Treatment focuses on slowing tumor growth and palliation of symptoms.

Renal Tumors

Localized renal cell carcinoma is treated with radical nephrectomy or nephron-sparing surgery. Prognosis drops precipitously if the tumor extends outside the kidney capsule because chemotherapy is relatively ineffective against metastatic renal cell carcinoma.

Bone Cancer and Bone Metastases

Primary bone cancers are extremely rare, accounting for less than 0.2% of all cancers. Bone metastases are more common, with clinical complications including debilitating bone pain. Treatment for bone metastases is performed to relieve local bone pain, provide stabilization, and prevent impending fracture or spinal cord compression.

KEY POINTS:

The most recent literature search was performed through June 6, 2023.

Summary of Evidence

For individuals with early stage kidney cancer who are surgical candidates treated with cryoablation, the evidence includes comparative observational studies and systematic reviews. Relevant outcomes are overall survival (OS), disease-specific survival, quality of life, and treatment-related morbidity. Multiple comparative observational studies and systematic reviews of these studies have compared cryoablation to partial nephrectomy for early stage renal cancer. These studies have consistently found that partial nephrectomy is associated with better oncological outcomes than cryosurgery, but cryosurgery was associated with better perioperative outcomes, lower incidence of complications, and less decline in kidney function. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with early stage kidney cancer who are not surgical candidates and who are treated with cryoablation, the evidence includes comparative observational studies of cryoablation compared to partial nephrectomy or other ablative techniques, systematic reviews of these studies, and case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. Although oncological outcomes were better with surgery, in comparative observational studies, cryoablation was associated with less decline in kidney function. Recent case series totaling more than 400 patients showed cryoablation was associated with good oncological outcomes and preservation of renal function. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with non-small cell lung cancer (NSCLC) who are not surgical candidates, the evidence includes uncontrolled observational studies and case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. Medically inoperable patients with early stage primary lung tumors were treated with cryoablation in a consecutive series of 45 patients. Five year survival was 68%; the main complications were hemoptysis in 40% of patients and pneumothorax in 51%. A prospective single arm Phase 2 study of 128 patients reported on cryoablation for treatment of metastases to the lung. Cryoablation for metastatic lung cancer was studied in a single arm trial in 40 patients. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with NSCLC who require palliation for a central airway obstructing lesion who are treated with cryoablation, the evidence includes case series. Relevant outcomes are OS,

disease-specific survival, quality of life, and treatment-related morbidity. There are no comparative studies. A series of 521 consecutive patients reported improvement in symptoms in 86% of patients, but multiple study design, conduct, and relevance limitations preclude drawing conclusions about efficacy or safety of cryoablation in this population. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with solid tumors located in the breast, pancreas, or bone who are treated with cryoablation, the evidence includes uncontrolled observational studies and case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. Due to the lack of prospective controlled trials, it is not possible to conclude that cryoablation improves outcomes for any indication better than alternative treatments. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

American College of Radiology

The American College of Radiology Appropriateness Criteria (2009, updated 2021) for post-treatment follow-up and active surveillance of renal cell carcinoma [RCC] indicated that "Ablative therapies, such as radiofrequency ablation, microwave ablation, and cryoablation, have been shown to be effective and safe alternatives [to surgical resection] for the treatment of small, localized RCCs." These recommendations are based on a review of the data and expert consensus.

American Urological Association

In 2021, the American Urological Association updated its guidelines on evaluation and management of clinically localized sporadic renal masses suspicious for renal cell carcinoma. The guideline statements on thermal ablation (radiofrequency ablation and cryoablation) are listed in Table 7.

Table 7. Guidelines on Localized Masses Suspicious for Renal Cell Carcinoma

Recommendations	LOR	LOE
Guideline statement 25		
Clinicians should consider thermal ablation (TA) as an alternate approach for the management of cT1a renal masses <3 cm in size. For patients who elect TA, a percutaneous technique is preferred over a surgical approach whenever feasible to minimize morbidity.	Moderate	C
Guideline statement 26		
Both radiofrequency ablation (RFA) and cryoablation may be offered as	Conditional	C

options for patients who elect thermal ablation		
Guideline statement 28		
Counseling about thermal ablation should include information regarding an increased likelihood of tumor persistence or local recurrence after primary thermal ablation relative to surgical excision, which may be addressed with repeat ablation if further intervention is elected	Strong	B

LOE: level of evidence; LOR: level of recommendation.

National Comprehensive Cancer Network

Kidney Cancer

The National Comprehensive Network (NCCN) (v.4.2023) guidelines on kidney cancer state that "thermal ablation (cryosurgery, radiofrequency ablation) is an option for the management of patients with clinical stage T1 renal lesions. Thermal ablation is an option for masses <3 cm, but may also be an option for larger masses in select patients. Ablation in masses >3 cm is associated with higher rates of local recurrence/persistence and complications. Biopsy of small lesions confirms a diagnosis of malignancy for surveillance, cryosurgery, and radiofrequency ablation strategies. Ablative techniques may require multiple treatments to achieve the same local oncologic outcomes as conventional surgery. The NCCN guidelines also note that "ablative techniques such as cryotherapy- or radiofrequency ablation are alternative strategies for selected patients, particularly the elderly and those with competing health risks." NCCN guidelines also note that "Randomized phase III comparison of ablative techniques with surgical resection (ie, radical or partial nephrectomy by open or laparoscopic techniques) has not been performed.

Non-Small Cell Lung Cancer

The NCCN (v. 3.2023) guidelines for NSCLC made the following relevant recommendations:

- Resection is the preferred local treatment modality for medically operable disease.
- Image-guided thermal ablation (IGTA) techniques include radiofrequency ablation, microwave ablation, and cryoablation.
- IGTA may be an option for select patients not receiving stereotactic ablative radiotherapy or definitive radiotherapy.
- IGTA may be considered for those patients who are deemed "high risk"- those with tumors that are for the most part surgically resectable but rendered medically inoperable due to comorbidities. In cases where IGTA is considered for high-risk or borderline operable patients, a multidisciplinary evaluation is recommended.
- IGTA is an option for the management of NSCLC lesions <3 cm. Ablation for NSCLC lesions >3 cm may be associated with higher rates of local recurrence and complications.
- The guidelines do not separate out recommendations by ablation technique and note that "each energy modality has advantages and disadvantages. Determination of energy modality to be used for ablation should take into consideration the size and location of

the target tumor, risk of complication, as well as local expertise and/or operator familiarity."

Cancer Pain

The NCCN Guidelines on Adult Cancer Pain (v.1.2023) do not address cryoablation specifically for pain due to bone metastases, but note that "ablation techniques may...be helpful for pain management in patients who receive inadequate relief from pharmacological therapy.

U.S. Preventive Services Task Force Recommendations

Cryoablation/cryosurgery is not a preventive service.

KEY WORDS:

Renal cell carcinoma, RCC, cryoablation, cryosurgery, cryosurgical ablation, cryotherapy, breast cancer, pancreatic cancer, breast fibroadenoma, lung cancer, bone cancer, metastatic bone cancer, Cryocare[®] Surgical System, CryoGen Cryosurgical System, CryoHit[®], SeedNet[™] System, Visica[®], IceSense2[™], IceSense3[™], ablation, fibroadenoma, breast ablation, breast cryoablation, pulmonary tumors, lung cancer, cryoablation of pulmonary tumor, cryoablation of lung tumor, desmoid tumors

APPROVED BY GOVERNING BODIES:

Several cryoablation devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for use in open, minimally invasive or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, proctology, thoracic surgery and ear; nose; and throat. Examples include:

- Cryocare[®] Surgical System by Endocare;
- CryoGen Cryosurgical System by Cryosurgical, Inc.;
- CryoHit[®] by Galil Medical for the treatment of breast fibroadenoma;
- IceSense3[™], ProSense[™], and MultiSense Systems (IceCure Medical);
- SeedNet[™] System by Galil Medical; and
- Visica[®] System by Sanarus Medical.

BENEFIT APPLICATION:

Coverage is subject to member's specific benefits. Group-specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT codes:

19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma
19499	Unlisted procedure, breast
20983	Ablation therapy for reduction or eradication of 1 or more bone tumors (e.g., metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation
32994	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation (Effective 01/01/2018)
48999	Unlisted procedure, pancreas
50250	Ablation, open, one or more renal mass lesion(s), cryosurgical, including intra-operative ultrasound guidance and monitoring, if performed
50542	Laparoscopy, surgical; ablation of renal mass lesion(s), including intra-operative ultrasound guidance and monitoring, when performed.
50593	Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral (Effective 01/01/20)

PREVIOUS CODING:

0340T	Ablation, pulmonary tumor(s), including pleura or chest wall when involved by tumor extension, percutaneous, cryoablation, unilateral, includes imaging guidance (Deleted effective 01/01/2018)
-------	---

REFERENCES:

1. American College of Radiology (ACR). ACR Appropriateness Criteria: Post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. Updated 2021. <https://acsearch.acr.org/docs/69365/Narrative/>.
2. American Society of Breast Surgeons. Official Statements: Position Statement on Ablative and Percutaneous Treatment of Breast Cancer. www.breastsurgeons.org.

3. American Society of Breast Surgeons. Consensus Statement: Management of Fibroadenomas of the Breast. Revised, April 29, 2008. Available online at: www.breastsurgeons.org/new_layout/about/statements/PDF_Statements/Fibroadenoma.pdf
4. Andrews JR, Atwell T, Schmit G, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for T1 Renal Masses. *Eur Urol*. Aug 2019; 76(2): 244-251.
5. Atkins Michael B and Richie Jerome P. Surgical management of renal cell carcinoma. www.uptodate.com.
6. Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). *J Thorac Oncol*. Jul 2020; 15(7): 1200-1209.
7. Callstrom MR and Kurup AN. Percutaneous ablation for bone and soft tissue metastases--why cryoablation? *Skeletal Radiology* 2009; 38: 835-839.
8. Callstrom MR, Dupuy DE, Solomon SB et al. Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. *Cancer* Mar 01 2013; 119(5):1033-41.
9. Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. *J Urol*. Aug 2021; 206(2): 199-208.
10. Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA Guideline. *J Urol*. Sep 2017; 198(3):520-529.
11. Caputo PA, Ramirez D, Zargar H, et al. Laparoscopic cryoablation for renal cell carcinoma: 100-Month Oncologic Outcomes. *J Urol*. Oct 2015; 194(4):892-896.
12. Casalino DD, Francis IR, Arellano RS et al. Expert Panel on Urologic Imaging. ACR Appropriateness Criteria®. Post-treatment follow-up of renal cell carcinoma acsearch.acr.org/docs/69365/Narrative/
13. Cronan J, Dariushnia S, Bercu Z, et al. Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards. *Semin Intervent Radiol*. Aug 2019; 36(3): 194-202.
14. de Baere T, Tselikas L, Woodrum D, et al. Evaluating cryoablation of metastatic lung tumors in patients--safety and efficacy: the ECLIPSE trial--interim analysis at 1 year. *J Thorac Oncol*. Oct 2015; 10(10):1468-1474.
15. Edwards MJ, et al. Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice, *The American Journal of Surgery* 2004, Vol. 188, pp 221-224.
16. El Dib R, Touma NJ, Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. *BJU Int* 2012.
17. Golatta M, Harcos A, Pavlista D et al. Ultrasound-guided cryoablation of breast fibroadenoma: a pilot trial. *Arch Gynecol Obstet*, June 2015, 291(6): 1355-1360.
18. Hahn M, Pavlista D, Danes J et al. Ultrasound guided cryoablation of fibroadenomas. *Ultraschall in Med*, November 2012.

19. IOM (Institute of Medicine). 2011. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press.
20. Jennings JW, Prologo JD, Garnon J, et al. Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study. Radiol Imaging Cancer. Mar 2021; 3(2): e200101.
21. Keane MG, Bramis K, Pereira SP et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol Mar 07 2014; 20(9):2267-78.
22. Klatte T, Grubmuller B, Waldert M et al. Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. Eur Urol 2011; 60(3):435-43.
23. Klatte T, Shariat SF, Remzi M. Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. J Urol May 2014; 191(5):1209-17.
24. Kunath F, Schmidt S, Krabbe LM, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev. May 09 2017; 5:CD012045.
25. Lee SH, Choi WJ, Sung SW et al. Endoscopic cryotherapy of lung and bronchial tumors: a systematic review. Korean J Intern Med Jun 2011; 26(2):137-44.
26. Li J, Chen X, Yang H et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J Feb 2011; 87(1024):89-95.
27. Lim E, Kumar S, Seager M, et al. Outcomes of Renal Tumors Treated by Image-Guided Percutaneous Cryoablation: Immediate and 3- and 5-Year Outcomes at a Regional Center. AJR Am J Roentgenol. Apr 14 2020: 1-6.
28. Long CJ, Kutikov A, Canter DJ et al. Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? BJU Int 2011; 107(9):1376-80.
29. Manenti G, Perretta T, Gaspari E et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. Eur Radiol Nov 2011; 21(11):2344-53.
30. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? Diagn Interv Radiol 2013; 19(6):501-7.
31. Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. Mar 2015; 26(3):312-319.
32. Morkos J, Porosnicu Rodriguez KA, Zhou A, et al. Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database. Radiology. Aug 2020; 296(2): 452-459.
33. Murray CA, Welch BT, Schmit GD, et al. Safety and Efficacy of Percutaneous Image-guided Cryoablation of Completely Endophytic Renal Masses. Urology. Nov 2019; 133: 151-156.

34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2.2022.
www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2023.
www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
36. National Comprehensive Cancer Network. Adult Cancer Pain. Version 1. 2023.
www.nccn.org/professionals/physician_gls/pdf/pain.pdf.
37. National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (V2.2018). Available online at:
www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
38. National Comprehensive Cancer Network® (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer (V.2.2019). Available online at:
www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
39. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. (V.2.2019). Available online at:
www.nccn.org/professionals/physician_gls/pdf/bone.pdf.
40. Niu L, Mu F, Zhang C et al. Cryotherapy protocols for metastatic breast cancer after failure of radical surgery. *Cryobiology* Aug 2013; 67(1): 17-22.
41. Niu L, Xu K, Mu F. Cryosurgery for lung cancer. *J Thorac Dis* Aug 2012; 4(4):408-19.
42. Pecoraro A, Palumbo C, Knipper S, et al. Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. *J Urol*. Dec 2019; 202(6): 1120-1126.
43. Pessoa RR, Autorino R, Laguna MP, et al. Laparoscopic versus percutaneous cryoablation of small renal mass: systematic review and cumulative analysis of comparative studies. *Clin Genitourin Cancer*. Oct 2017; 15(5):513-519 e515.
44. Purysko AS, Nikolaidis P, Khatri G, et al. ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update. *J Am Coll Radiol*. May 2022; 19(5S): S156-S174.
45. Purysko AS, Nikolaidis P, Dogra VS, et al. ACR Appropriateness Criteria(R) Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer. *J Am Coll Radiol*. Nov 2019; 16(11S): S399-S416.
46. Ratko TA, Vats V, Brock J et al. Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer. Rockville, MD: Agency for Healthcare Research and Quality, 2013.
47. Rembeyo G, Correias JM, Jantzen R, et al. Percutaneous Ablation Versus Robotic Partial Nephrectomy in the Treatment of cT1b Renal Tumors: Oncologic and Functional Outcomes of a Propensity Score-weighted Analysis. *Clin Genitourin Cancer*. Apr 2020; 18(2): 138-147.
48. Rodriguez R, Cizman Z, Hong K. Prospective analysis of the safety and efficacy of percutaneous cryoablation for pT1NxMx biopsy-proven renal cell carcinoma. *Cardiovasc Intervent Radiol* 2011; 34(3):573-8.

49. Sewell Patrick E and Shingleton W Bruce. Percutaneous renal tumor cryoablation with magnetic resonance imaging guidance. GE Healthcare-Clinical Case Studies. www.gehealthcare.com.
50. Simmons RM, Ballman KV, Cox C, et al. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (Alliance) Z1072. *Ann Surg Oncol*. Aug 2016; 23(8): 2438-45.
51. Stacul F, Sachs C, Giudici F, et al. Cryoablation of renal tumors: long-term follow-up from a multicenter experience. *Abdom Radiol (NY)*. Sep 2021; 46(9): 4476-4488.
52. Strom KH, Derweesh I, Stroup SP et al. Second prize: recurrence rates after percutaneous and laparoscopic renal cryoablation of small renal masses: does the approach make a difference? *J Endourol* 2011; 25(3):371-5.
53. Tang K, Yao W, Li H et al. Laparoscopic Renal Cryoablation versus Laparoscopic Partial Nephrectomy for the Treatment of Small Renal Masses: A Systematic Review and Meta-analysis of Comparative Studies. *J Laparoendosc Adv Surg Tech A* Jun 2014; 24(6):403-10.
54. Tao Z, Tang Y, Li B et al. Safety and Effectiveness of Cryosurgery on Advanced Pancreatic Cancer: A Systematic Review. *Pancreas* 2012; 41(5):809-11.
55. Uhlig J, Strauss A, Rücker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. *Eur Radiol*. 2019 Mar;29(3):1293-1307.
56. Van Poppel H, Becker F, Cadeddu JA et al. Treatment of localised renal cell carcinoma. *Eur Urol* 2011; 60(4):662-72.
57. Wu J, Chang J, Bai HX, et al. A Comparison of Cryoablation with Heat-Based Thermal Ablation for Treatment of Clinical T1a Renal Cell Carcinoma: A National Cancer Database Study. *J Vasc Interv Radiol*. Jul 2019; 30(7): 1027-1033.e3.
58. Yanagisawa T, Mori K, Kawada T, et al. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. *Urol Oncol*. Jul 2022; 40(7): 315-330.
59. Yan S, Yang W, Zhu CM, et al. Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2-4 cm: A population-based study. *Medicine (Baltimore)*. May 2019; 98(21): e15610.
60. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. *Eur J Surg Oncol*. Dec2010; 36(12): 1149-55.

POLICY HISTORY:

Medical Policy Group, January 2004

Available for comment February 7-March 22, 2004

Medical Policy Group, January 2006

Medical Policy Group, October 2007

Available for comment November 17-December 31, 2007

Medical Policy Group, March 2009
Medical Policy Group, October 2009
Available for comment November 6-December 21, 2009
Medical Policy Group, June 2010
Available for comment July 2-August 16, 2010
Medical Policy Group, November 2010 CPT Code update
Medical Policy Group, March 2011
Available for comment April 4 – May 18, 2011
Medical Policy Group, July 2011
Medical Policy Group, April 2013
Available for comment April 18 through June 5, 2013
Medical Policy Group, September 2013
Available for comment September 24 through November 7, 2013
Medical Policy Group, December 2013
Medical Policy Group, July 2014
Medical Policy Group, February 2015
Medical Policy Group, July 2015
Medical Policy Group, August 2016
Medical Policy Group, November 2017
Available for comment November 30, 2017, through January 13, 2018
Medical Policy Group, August 2018 (4): Updates to Description, Key Points, and References.
No change to policy statement.
Medical Policy Group, July 2019
Medical Policy Group, July 2020
Medical Policy Group, July 2021
Medical Policy Group, September 2021
Medical Policy Group, July 2022
Medical Policy Group, July 2023
UM Committee, December 2023: Policy approved by UM Committee for use for Blue Advantage business.

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.